Literature DB >> 16377426

Antibody formation against beta-tubulin class III in response to brain trauma.

D Skoda1, K Kranda, M Bojar, L Glosová, J Bäurle, J Kenney, D Romportl, M Pelichovská, K Cvachovec.   

Abstract

Brain trauma typically leads to neuronal damage and loss. Assuming a transient autoimmune response to debris of the damaged neurones, we have monitored serum titres of IgG and IgM antibodies to beta-tubulin class III (betaTcIII), which is almost exclusively found in neuronal cytoskeletons. In 15 out of 18 patients, the peak of the IgG or IgM antibody titre appeared in the serum within 3 weeks of a brain trauma.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16377426     DOI: 10.1016/j.brainresbull.2005.05.032

Source DB:  PubMed          Journal:  Brain Res Bull        ISSN: 0361-9230            Impact factor:   4.077


  6 in total

1.  Identification of autoantibodies to glial fibrillary acidic protein in spinal cord injury patients.

Authors:  Georgene W Hergenroeder; Anthony N Moore; Karl M Schmitt; John B Redell; Pramod K Dash
Journal:  Neuroreport       Date:  2016-01-20       Impact factor: 1.837

Review 2.  Need for a paradigm shift in therapeutic approaches to CNS injury.

Authors:  Bharath Wootla; Aleksandar Denic; Arthur E Warrington; Moses Rodriguez
Journal:  Expert Rev Neurother       Date:  2012-04       Impact factor: 4.618

3.  B cells and autoantibodies: complex roles in CNS injury.

Authors:  Daniel P Ankeny; Phillip G Popovich
Journal:  Trends Immunol       Date:  2010-08-04       Impact factor: 16.687

4.  Increased Levels of Circulating Glial Fibrillary Acidic Protein and Collapsin Response Mediator Protein-2 Autoantibodies in the Acute Stage of Spinal Cord Injury Predict the Subsequent Development of Neuropathic Pain.

Authors:  Georgene W Hergenroeder; John B Redell; H Alex Choi; Lisa Schmitt; William Donovan; Gerard E Francisco; Karl Schmitt; Anthony N Moore; Pramod K Dash
Journal:  J Neurotrauma       Date:  2018-07-05       Impact factor: 5.269

5.  Avidity of anti-neurocytoskeletal antibodies in cerebrospinal fluid and serum.

Authors:  L Fialová; J Švarcová; A Bartos; I Malbohan
Journal:  Folia Microbiol (Praha)       Date:  2012-05-08       Impact factor: 2.099

6.  Antibody profiling identifies novel antigenic targets in spinal cord injury patients.

Authors:  Ilse Palmers; Elke Ydens; Eric Put; Bart Depreitere; Helma Bongers-Janssen; Peter Pickkers; Sven Hendrix; Veerle Somers
Journal:  J Neuroinflammation       Date:  2016-09-13       Impact factor: 8.322

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.